GI
ESPR

GAMMA Investing’s Esperion Therapeutics ESPR Stock Holding History

GAMMA Investing’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446 Buy
141
+71
+101% +$199 ﹤0.01% 4002
2026
Q1 		$192 Sell
70
-453
-87% -$1.43K ﹤0.01% 4061
2025
Q4 		$1.94K Buy
+523
New +$1.69K ﹤0.01% 3608

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

GAMMA Investing's ESPR Position: Q2 2026 in Review

GAMMA Investing increased its Esperion Therapeutics (ESPR) stake by 101% in Q2 2026, buying an estimated $199 and bringing the position to 141 shares worth $446. The position accounts for ﹤0.01% of the portfolio, ranked #4002.

GAMMA Investing first reported a position in ESPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.94K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • GAMMA Investing held 141 shares of Esperion Therapeutics worth $446 as of Q2 2026.
  • GAMMA Investing bought 71 Esperion Therapeutics shares in Q2 2026, an estimated $199.
  • Esperion Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4002 holding.
  • GAMMA Investing first reported a position in Esperion Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GAMMA Investing's Esperion Therapeutics position peaked at $1.94K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.